Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.

Miano ST, Francini E, Petrioli R, Francini G.

Future Oncol. 2020 Jan;16(1s):33-38. doi: 10.2217/fon-2019-0600.

PMID:
31975628
2.

Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.

Petrioli R, Mazzei MA, Giorgi S, Cesqui E, Gentili F, Francini G, Volterrani L, Francini E.

Anticancer Drugs. 2020 Feb;31(2):190-195. doi: 10.1097/CAD.0000000000000864.

PMID:
31850916
3.

Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.

Petrioli R, Francini E, Cherri S, Marrelli D, Rovello F, Fiaschi AI, Miano ST, Savelli V, Calomino N, Farsi M, Vernillo R, Francini G.

Anticancer Drugs. 2019 Dec 14. doi: 10.1097/CAD.0000000000000877. [Epub ahead of print]

PMID:
31850915
4.

Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.

Petrioli R, Marrelli D, Roviello F, D'Ignazio A, Torre P, Chirra M, Savelli V, Ambrosio MR, Francini G, Calomino N, Farsi M, Vernillo R, Francini E.

Surg Oncol. 2019 Oct 2;32:2-7. doi: 10.1016/j.suronc.2019.10.002. [Epub ahead of print]

PMID:
31670056
5.

Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer.

Petrioli R, Torre P, Pesola G, Paganini G, Paolelli L, Miano ST, Martellucci I, Francini G, Francini E.

J Geriatr Oncol. 2019 Aug 27. pii: S1879-4068(19)30130-4. doi: 10.1016/j.jgo.2019.08.008. [Epub ahead of print]

PMID:
31471168
6.

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights.

Roviello G, D'Angelo A, Roudi R, Petrioli R, Mini E.

J Oncol. 2019 Jul 4;2019:5692317. doi: 10.1155/2019/5692317. eCollection 2019. Review.

7.

Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel.

Roviello G, Corona SP, Multari AG, Petrioli R, Rosellini P, Aieta M.

Anticancer Drugs. 2019 Aug;30(7):e0789. doi: 10.1097/CAD.0000000000000789.

PMID:
31305296
8.

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

Roviello G, Corona SP, Conca R, Petrioli R, Rosellini P, Bonetta A, Aieta M.

Medicine (Baltimore). 2019 Jun;98(26):e16249. doi: 10.1097/MD.0000000000016249.

9.

Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?

Roviello G, Sohbani N, Petrioli R, Rodriquenz MG.

Invest New Drugs. 2019 Dec;37(6):1274-1288. doi: 10.1007/s10637-019-00760-0. Epub 2019 Mar 16. Review.

PMID:
30879152
10.

The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.

Roviello G, Petrioli R, Rosellini P, Multari AG, Conca R, Paganini G, Chiriacò G, Aieta M.

Invest New Drugs. 2019 Jun;37(3):524-530. doi: 10.1007/s10637-019-00725-3. Epub 2019 Jan 28.

PMID:
30687871
11.

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.

Roviello G, Petrioli R, Bonetta A, Conca R, Rodriquenz MG, Aieta M.

Invest New Drugs. 2018 Dec;36(6):1110-1115. doi: 10.1007/s10637-018-0685-7. Epub 2018 Oct 22.

PMID:
30345466
12.

Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.

Petrioli R, Francini E, Cherri S, Torre P, Fiaschi AI, Miano ST, Marrelli D, Rovello F, Francini G.

Clin Colorectal Cancer. 2018 Dec;17(4):e663-e669. doi: 10.1016/j.clcc.2018.07.002. Epub 2018 Jul 4.

PMID:
30153975
13.

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Roviello G, Corona SP, Multari AG, Paganini G, Chiriacò G, Conca R, Petrioli R, Generali D, Rosellini P, Aieta M.

Oncotarget. 2018 Apr 27;9(32):22332-22339. doi: 10.18632/oncotarget.24900. eCollection 2018 Apr 27.

14.

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.

Roviello G, Petrioli R, Nardone V, Rosellini P, Multari AG, Conca R, Aieta M.

Medicine (Baltimore). 2018 May;97(20):e10745. doi: 10.1097/MD.0000000000010745.

15.

Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.

Petrioli R, Chirra M, Messuti L, Fiaschi AI, Savelli V, Martellucci I, Francini E.

Clin Colorectal Cancer. 2018 Dec;17(4):307-312. doi: 10.1016/j.clcc.2018.02.005. Epub 2018 Feb 21.

PMID:
29548772
16.

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, Generali D.

Eur J Cancer. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24. Review.

PMID:
28242502
18.

Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis.

Petrioli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D, Generali D.

Crit Rev Oncol Hematol. 2016 Jun;102:82-8. doi: 10.1016/j.critrevonc.2016.04.001. Epub 2016 Apr 8. Review.

PMID:
27083592
19.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.

Polom K, Roviello G, Generali D, Marano L, Petrioli R, Marsili S, Caputo E, Marrelli D, Roviello F.

Int J Hyperthermia. 2016 May;32(3):298-310. doi: 10.3109/02656736.2016.1149233. Epub 2016 Mar 17. Review.

PMID:
26984715
20.

Gastric cancer: Current status of lymph node dissection.

Degiuli M, De Manzoni G, Di Leo A, D'Ugo D, Galasso E, Marrelli D, Petrioli R, Polom K, Roviello F, Santullo F, Morino M.

World J Gastroenterol. 2016 Mar 14;22(10):2875-93. doi: 10.3748/wjg.v22.i10.2875. Review.

21.

Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.

Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D, Roviello F, Generali D.

Cancer Lett. 2016 Mar 28;372(2):187-91. doi: 10.1016/j.canlet.2016.01.014. Epub 2016 Jan 18. Review.

PMID:
26797419
22.

Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence.

Polom K, Marano L, Roviello G, Petrioli R, Piagnerelli R, de Franco L, Marrelli D, Roviello F.

Int J Hyperthermia. 2016;32(2):173-9. doi: 10.3109/02656736.2015.1111432. Epub 2015 Dec 15.

PMID:
26670720
23.

Surgical management of advanced gastric cancer: An evolving issue.

Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A, De Luca R, Petrioli R, Martinotti M, Generali D, Marrelli D, Di Martino N, Roviello F.

Eur J Surg Oncol. 2016 Jan;42(1):18-27. doi: 10.1016/j.ejso.2015.10.016. Epub 2015 Nov 14. Review.

PMID:
26632080
24.

Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.

Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F.

Tumour Biol. 2016 Jan;37(1):127-40. doi: 10.1007/s13277-015-4408-9. Epub 2015 Nov 13. Review.

PMID:
26566626
25.

Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer.

Marrelli D, Polom K, Pascale V, Vindigni C, Piagnerelli R, De Franco L, Ferrara F, Roviello G, Garosi L, Petrioli R, Roviello F.

Ann Surg Oncol. 2016 Mar;23(3):943-50. doi: 10.1245/s10434-015-4931-3. Epub 2015 Nov 3.

PMID:
26530444
26.

Is there still a place for docetaxel rechallenge in prostate cancer?

Petrioli R, Francini E, Roviello G.

World J Clin Oncol. 2015 Oct 10;6(5):99-103. doi: 10.5306/wjco.v6.i5.99.

27.

An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.

Roviello G, Francini E, Perrella A, Laera L, Mazzei MA, Guerrini S, Petrioli R.

Cancer Biol Ther. 2015;16(12):1720-5. doi: 10.1080/15384047.2015.1095410.

28.

Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.

Piagnerelli R, Marrelli D, Roviello G, Ferrara F, Di Mare G, Voglino C, Petrioli R, Marini M, Macchiarelli R, Roviello F.

Tumour Biol. 2016 Feb;37(2):1959-66. doi: 10.1007/s13277-015-3986-x. Epub 2015 Sep 3.

PMID:
26334620
29.

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

Roviello G, Petrioli R, Marano L, Polom K, Marrelli D, Perrella A, Roviello F.

Gastric Cancer. 2016 Jan;19(1):31-41. doi: 10.1007/s10120-015-0537-5. Epub 2015 Sep 2. Review.

PMID:
26329368
30.

Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, Marrelli D, Roviello F, Bianco V, Francini E.

Future Oncol. 2015 Sep;11(18):2563-74. doi: 10.2217/fon.15.105. Epub 2015 Aug 28.

PMID:
26314701
31.

Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.

Petrioli R, Francini E, Roviello F, Marrelli D, Miano ST, Fiaschi AI, Laera L, Bellini MA, Roviello G.

J Geriatr Oncol. 2015 Sep;6(5):380-6. doi: 10.1016/j.jgo.2015.06.002. Epub 2015 Jul 27.

PMID:
26228711
32.

Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.

Francini E, Fiaschi AI, Petrioli R, Bianco V, Laera L, Francini F, Roviello G.

Anticancer Drugs. 2015 Sep;26(8):910-1. doi: 10.1097/CAD.0000000000000258. No abstract available.

PMID:
26207428
33.

Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.

Petrioli R, Francini E, Laera L, Fiaschi AI, Ponchietti R, Roviello G.

Cancer Chemother Pharmacol. 2015 Sep;76(3):439-45. doi: 10.1007/s00280-015-2803-y. Epub 2015 Jun 17. Review.

PMID:
26082421
34.

Short-term and long-term risk factors in gastric cancer.

Verlato G, Marrelli D, Accordini S, Bencivenga M, Di Leo A, Marchet A, Petrioli R, Zoppini G, Muggeo M, Roviello F, de Manzoni G.

World J Gastroenterol. 2015 Jun 7;21(21):6434-43. doi: 10.3748/wjg.v21.i21.6434.

35.

Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.

Petrioli R, Roviello G, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Martellucci I, Bianco V, Francini E.

Clin Lung Cancer. 2015 Nov;16(6):e229-34. doi: 10.1016/j.cllc.2015.05.005. Epub 2015 May 18.

PMID:
26072097
36.

Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.

Francini E, Fiaschi AI, Petrioli R, Laera L, Bianco V, Ponchietti R, Roviello G.

Anticancer Drugs. 2015 Sep;26(8):884-7. doi: 10.1097/CAD.0000000000000257.

PMID:
26053281
37.

Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, Bianco V, Francini E.

Anticancer Drugs. 2015 Sep;26(8):878-83. doi: 10.1097/CAD.0000000000000254.

PMID:
26053279
38.

The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Roviello G, Petrioli R, Laera L, Francini E.

Crit Rev Oncol Hematol. 2015 Sep;95(3):265-71. doi: 10.1016/j.critrevonc.2015.04.010. Epub 2015 May 21. Review.

PMID:
26052050
39.

c-Met targeting in advanced gastric cancer: An open challenge.

Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A.

Cancer Lett. 2015 Aug 28;365(1):30-6. doi: 10.1016/j.canlet.2015.05.028. Epub 2015 Jun 3. Review.

PMID:
26049023
40.

Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.

Petrioli R, Francini E, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Roviello G.

Anticancer Res. 2015 May;35(5):3097-102.

PMID:
25964601
41.

Targeted Therapies for Prostate Cancer.

Petrioli R, Francini E, Fiaschi AI, Laera L, Roviello G.

Cancer Invest. 2015;33(7):276-85. doi: 10.3109/07357907.2015.1033105. Epub 2015 May 7. Review.

PMID:
25951372
42.

Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Bianco V, Ponchietti R, Barbanti G, Francini E.

Clin Genitourin Cancer. 2015 Oct;13(5):441-6. doi: 10.1016/j.clgc.2015.03.004. Epub 2015 Mar 26.

PMID:
25920994
43.

Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: A brief overview of recent results.

Roviello F, Roviello G, Petrioli R, Marrelli D.

Crit Rev Oncol Hematol. 2015 Sep;95(3):297-305. doi: 10.1016/j.critrevonc.2015.03.007. Epub 2015 Apr 11. Review.

PMID:
25900072
44.

Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Roviello F, Marrelli D, Francini E.

Anticancer Drugs. 2015 Jul;26(6):682-6. doi: 10.1097/CAD.0000000000000233.

PMID:
25811963
45.

Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.

Petrioli R, Francini E, Fiaschi AI, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Bianco V, Roviello G.

Med Oncol. 2015 Apr;32(4):134. doi: 10.1007/s12032-015-0587-x. Epub 2015 Mar 22.

PMID:
25796503
46.

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.

Petrioli R, Francini E, Roviello F, Marrelli D, Fiaschi AI, Laera L, Rossi G, Bianco V, Brozzetti S, Roviello G.

Cancer Chemother Pharmacol. 2015 May;75(5):941-7. doi: 10.1007/s00280-015-2715-x. Epub 2015 Mar 6.

PMID:
25743995
47.

Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer.

Roviello G, Francini E, Perrella A, Laera L, Mazzei MA, Guerrini S, Roviello F, Marrelli D, Petrioli R.

Cancer Biol Ther. 2015;16(4):493-7. doi: 10.1080/15384047.2015.1017692. Epub 2015 Feb 26.

48.

Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S, Francini E.

Med Oncol. 2015 Mar;32(3):52. doi: 10.1007/s12032-015-0485-2. Epub 2015 Jan 31.

PMID:
25636506
49.

Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Marrelli D, Roviello F, Francini E.

Cancer Chemother Pharmacol. 2015 Apr;75(4):683-90. doi: 10.1007/s00280-015-2683-1. Epub 2015 Jan 25.

PMID:
25618415
50.

Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.

Francini E, Petrioli R, Fiaschi AI, Laera L, Roviello G.

Medicine (Baltimore). 2014 Dec;93(27):e163. doi: 10.1097/MD.0000000000000163.

Supplemental Content

Loading ...
Support Center